相关实验视频
Updated: Jun 3, 2025

08:09
A Doxorubicin-induced Cardiomyopathy Model in Adult Zebrafish
Published on: June 7, 2018
9.7K
肠道微生物组和代谢的改变与多克索鲁比诱导的心力衰竭的严重程度
Qian Wang1, Meihua Liu1,2, Tianpei Liu1,2
1Department of Cardiology, The Second Hospital of Shanxi Medical University, Taiyuan, China.
Frontiers in microbiology
|January 8, 2025
概括
多克索鲁比 (DOX) 通过改变肠道微生物群和代谢物引起心力衰竭. 这些变化与疾病严重程度相关,可能为多克索鲁比诱导心力衰竭 (DIHF) 提供新的治疗点.
科学领域:
- 心脏病学 心脏病学
- 微生物学 微生物学
- 代谢学 代谢学 代谢学
背景情况:
- 多克索鲁比 (DOX) 是一种具有已知心脏毒性的强效化疗剂.
- doxorubicin 诱导的心力衰竭 (DIHF) 是一个重大的临床挑战.
- 肠道微生物群在DIHF病理生理学中的作用尚未完全理解.
研究的目的:
- 在DIHF的不同阶段调查肠道微生物群和血清代谢物的变化.
- 探索肠道微生物群组成和DIHF中的代谢概况之间的相关性.
- 为了确定DIHF的潜在微生物和代谢生物标志物.
主要方法:
- 用DOX治疗小鼠以诱导心力衰竭.
- 评估了心脏功能和组织病理学.
- 进行了便16S rRNA测序和血清非向代谢.
- 多omics分析集成的微生物和代谢数据.
主要成果:
- DOX诱导心脏功能障碍和心肌酶水平升高.
- 观察到肠道微生物群组成和血清代谢物水平的显著变化.
- 在特定的肠道细菌和差异性血清代谢物之间发现了强烈的相关性.
- 确定了DIHF潜在的微生物和代谢生物标志物 (AUC > 0.8).
结论:
- DIHF的特点是独特的肠道微生物和代谢特征.
- 肠道微生物群的组成与DIHF的代谢变化有显著的相关性.
- 肠道微生物群代表了管理DIHF的有前途的治疗点.
相关概念视频
Pathophysiology of Heart Failure
1.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.5K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
381
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
381
Heart Failure Drugs: Inotropic Agents
515
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
515
Factors Influencing Drug Absorption: Disease States and Pharmacology
428
Multiple disease states can significantly influence the oral drug absorption process by affecting blood flow and the functionality of the gastrointestinal (GI) system. Various GI diseases, including conditions that alter GI motility, such as diarrhea, decreased acid secretions (achlorhydria), and infections, have been associated with reduced drug absorption.
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
Substances such as alcohol and specific drugs, including antineoplastics, can also negatively impact drug absorption. For instance,...
428
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338

